Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET

Company Participants

Chris Calabrese - LifeSci Advisors, LLC

Alexander Sapir - President and Chief Executive Officer

Iain Fraser - Interim Chief Medical Officer

Gregory Tourangeau - Principal Accounting Officer

Conference Call Participants

Benazir Ali - Stifel

Joseph Schwartz - Leerink Partners

Edward Tenthoff - Piper Sandler

Matthew Hagood - Oppenheimer

Judah Frommer - Credit Suisse

Operator

Good morning and welcome to the Fulcrum Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently all participants are in a listen-only mode. This call is being webcast live on the Investor Section of Fulcrum’s website at www.fulcrumtx.com and is being recorded.

Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, including the clinical hold on FTX-6058, clinical development time lines and financial projections. While these forward-looking statements represent Fulcrum's view as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so.

Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business.

Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call today are Dr. Iain Fraser, Interim Chief Medical Officer; and Greg Tourangeau, Fulcrum's Principal Accounting Officer. After providing updates on our key programs, there will be a brief Q&A in which Alex, Iain and Greg will be available to answer your questions.

With that, it is my pleasure to turn the call over to Alex. Please go ahead.

Alexander Sapir

Thank you, operator, and thanks to all of you for taking time to join us today. It's truly an honor for me to have the opportunity to lead Fulcrum at this important time and to build on the company's strong foundation as we work towards advancing our pipeline and delivering on our commitment to improve the lives of patients with rare genetic diseases.

So what I'd like to do this morning is to provide a brief update on our two key programs, losmapimod for Facioscapulohumeral Muscular Dystrophy or FSHD for short and FTX-6058 for sickle cell disease. After that, I'll provide a couple of corporate updates and then turn it over to Greg for financial highlights. And after Greg, we'll open it up for questions.